Sandoz

AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
AbbVie flexes litigation muscle with Rinvoq patent lawsuit against Sandoz, other generic players
Fierce Pharma
AbbVie
Rinvoq
patents
legal
Sandoz
Sun Pharma
Intas Pharmaceuticals
Flag link:
Novartis' Sandoz dips on debut after lower than expected valuation
Novartis' Sandoz dips on debut after lower than expected valuation
Reuters
Novartis
Sandoz
spinoffs
Flag link:
Novartis confirms Sandoz spin-off for October 4, 2023
Novartis confirms Sandoz spin-off for October 4, 2023
Reuters
Novartis
Sandoz
spinoffs
Flag link:
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara
BioSpace
Sandoz
Samsung Bioepis
biosimilars
JNJ
Stelara
Flag link:
Novartis updates on Sandoz finances ahead of spin-off
Novartis updates on Sandoz finances ahead of spin-off
Pharmaphorum
Novartis
Sandoz
spinoffs
generics
biosimilars
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Flag link:
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation
Biopharma Reporter
Novartis
Sandoz
spinoff
biosimilars
generics
Flag link:
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4
Fierce Pharma
Novartis
Sandoz
spinoffs
generics
biosimilars
Flag link:
Sandoz plans to enter the Eylea biosimilar race
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Sandoz
generics
biosimilars
Eylea
Novartis
wet age-related macular degeneration
Flag link:
Biosimilar makers split strategies in bid to take on top-selling Humira
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Flag link:
7 companies are rolling out Humira biosimilars
7 companies are rolling out Humira biosimilars
Drugstore News
AbbVie
Humira
biosimilars
Boehringer Ingelheim
Organon
Samsung Bioepsis
Sandoz
Fresenius Kabi
Celltrion
Coherus Biosciences
Biocon
Flag link:
Sanofi blocks Sandoz's Jevtana generic in patent win
Sanofi blocks Sandoz's Jevtana generic in patent win
Fierce Pharma
Sanofi
Jevtana
generics
Sandoz
prostate cancer
legal
Flag link:
Sandoz targets barriers to biosimilar accessibility with latest initiative
Sandoz targets barriers to biosimilar accessibility with latest initiative
Pharmaceutical Technology
Sandoz
Novartis
patient access
biosimilars
Flag link:
Sandoz hitches its wagon to biosimilars, predicting $3B in sales from pipeline products over next 5 years
Sandoz hitches its wagon to biosimilars, predicting $3B in sales from pipeline products over next 5 years
Fierce Pharma
Novartis
Sandoz
generics
biosimilars
Flag link:
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Novartis brings on 8 business vets for Sandoz's new board, including 4 women
Fierce Pharma
Novartis
Sandoz
biosimilars
generics
women executives
Flag link:
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Sandoz taps Evotec in long-term biosimilar development and manufacturing deal
Fierce Pharma
Novartis
Sandoz
Evotec
biosimilars
Flag link:
Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold
Novartis spruces up Sandoz—again—by bringing 6 new US generics into the fold
Fierce Pharma
Novartis
Sandoz
generics
Adalvo
Flag link:
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Yahoo/Benzinga
Amgen
Sandoz
legal
Prolia
Xgeva
patents
denosumab
Flag link:
Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028
Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028
Fierce Pharma
Amgen
Otezla
immunology
generics
Sandoz
Zydus
patents
Flag link:

Pages